5. 進行性核上性麻痺 [臨床試験数:82,薬物数:107(DrugBank:36),標的遺伝子数:60,標的パスウェイ数:90

Searched query = "Progressive supranuclear palsy", "PSP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2006-006166-42-DE17/07/200702/01/2007Exelon bei dementiellem Syndrom bei Patienten mit Progressiver Supranukleärer Parese -offene, prospektive Phase II-Studie -Exelon bei dementiellem Syndrom bei Patienten mit Progressiver Supranukleärer Parese -offene, prospektive Phase II-Studie - Progressive supranuclear palsy (PSP) is a neurodegenerative disorder with hardly any therapeutical option to ameliorate the course of the disease. Results of first trials with physostigmine and donepezil did not point out a definite benefit. In contrast, first clinical observations concerning an effect with rivastigmine in PSP with dementia were promising. This may be due to the fact, that rivastigmine excerts a double action inhibiting both the acetylcholin- and the buturylcholinesterase.Trade Name: Exelon 1,5 mg Hartkapseln
INN or Proposed INN: RIVASTIGMINE
Trade Name: Exelon 3,0 mg Hartkapseln
INN or Proposed INN: RIVASTIGMINE
Trade Name: Exelon 6,0 mg Hartkapseln
INN or Proposed INN: RIVASTIGMINE
University of TuebingenNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2Germany
2NCT00139373May 200530/8/2005Study of the Distractibility Syndrome in Patients With Progressive Supranuclear PalsyStudy of the Distractibility Syndrome in Patients With Progressive Supranuclear PalsySupranuclear Palsy, ProgressiveDrug: donepezilGroupe Hospitalier Pitie-SalpetriereInstitut National de la Santé Et de la Recherche Médicale, FranceRecruiting30 Years80 YearsBoth16Phase 2France